

NAME	POSITION TITLE	BIRHTDATE
Denis Fouque, M.D., Ph.D.	- Professor of Nephrology, University Lyon1 - Chief, Division of Nephrology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France - Past Vice-President Scientific Affairs, University Lyon1	4/14/60

Board registration (CNOM) 69/9923 (Ordre Médecins du Rhône, October 1989)

INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD
University Claude Bernard Lyon	M.D.	1979-1984	Medicine
University Claude Bernard Lyon	Ph.D.	1993-1996	Nutrition
Hospices Civils de Lyon, Internal Medicine	Internship	1984-1985	Rotating
Hospices Civils de Lyon, Internal Medicine	Residency	1985-1988	Residency
Hospices Civils de Lyon, Nephrology	Fellowship	1988-1990	Fellowship
Harbor-UCLA Med Center, Torrance, CA, USA	Research Fellowship	1992-1993	Fellowship
University Claude Bernard Lyon	Full Professor	1997	
Harbor-UCLA Med Center, Torrance, CA, USA	Invited Professor	2003	

PROFESSIONAL EXPERIENCE:

Research Master in Renal Physiology, University of Paris VII, France, 1985-1986
 Board Certified in Nephrology, UCBL School of Medicine, Lyon, France, 1989
 Certified in Clinical Pharmacology, UCBL School of Medicine, Lyon, France, 1992
 Certified in Methodology of Clinical Trials, UCBL School of Medicine, Lyon, France, 1992
 Assistant Professor of Medicine, UCBL School of Medicine, Lyon, France, 1990-1997
 Professor of Renal Medicine, University Claude Bernard, Lyon, France, 1997 to present

HONORS AND SOCIETIES:

Annual Award, French Association for Therapeutics (M.D. Thesis), 1990
 Annual Research Grant, French National Institute of Health and Medical Research (INSERM), 1992-1993, for a research fellowship at Harbor-UCLA Medical Center, Torrance, CA.
 Annual Lavoisier Grant, French Foreign Minister, 1992.
 French Society of Nephrology (1989 to present), International Society of Nephrology (1990 to present), International Society for Renal Nutrition and Metabolism (1991 to present), European Dialysis and Transplantation Association (1991 to present), Acute Renal Failure Task Force (1991 to present), American Society of Nephrology (1993 to present), National Kidney Foundation (1993 to present).
 Founder, Cochrane Renal Group for Evidence-based Nephrology (1997-2000)
 President, International Society for Renal Nutrition and Metabolism, 2004-2006
 Editor-in-Chief, Journal of Renal Nutrition, Philadelphia USA (2003-2011)
 Chevalier des Palmes Académiques 2015
Editor-in-Chief, Nephrology Dialysis Transplantation (2017-2022)

PUBLICATIONS: 350 international papers H Index: 64 Citations : 17600

ABSTRACTS: over 350 abstracts or oral presentations

INVITED LECTURES: 250 international conferences

BEST PUBLICATIONS SINCE 2010 (from a total of 350 papers published)

1. Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, **Fouque D**, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and

- cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. **Nephrol Dial Transplant**. 2019 Feb 1;34(2):208-230
2. Koppe L, **Fouque D**, Kalantar-Zadeh K. Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers. **J Cachexia Sarcopenia Muscle**. 2019 Apr 12. doi: 10.1002/jcsm.12421.
 3. Kalantar-Zadeh K, **Fouque D**. Nutritional Management of Chronic Kidney Disease. **N Engl J Med**. 2017 Nov 2;377(18):1765-1776
 4. Hahn D, Hodson EM, **Fouque D**. Low protein diets for non-diabetic adults with chronic kidney disease. **Cochrane Database Syst Rev**. 2018 Oct 4;10:CD001892 On line
 5. Koppe L, **Fouque D**. The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD. **Am J Kidney Dis**. 2018 Aug 24. On line
 6. **Fouque D**, Vervloet M, Ketteler M. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease. **Drugs**. 2018 Aug;78(12):1171-1186
 7. Zoccali C, Vanholder R, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, Fliser D, **Fouque D** et al. The systemic nature of CKD. **Nat Rev Nephrol**. 2017 Jun;13(6):344-358
 8. Marçais C, Maucourt-Boulch D, Drai J, Dantony E, Carlier MC, Blond E, Genet L, Kuentz F, Lataillade D, Legrand E, Moreau-Gaudry X, Jean G, **Fouque D**. Circulating Klotho Associates With Cardiovascular Morbidity and Mortality During Hemodialysis. **J Clin Endocrinol Metab**. 2017 Sep 1;102(9):3154-3161
 9. Vervloet M, Sezer S, Massy Z, Johannson L, Cozzolino M, **Fouque D**. An overview of phosphate metabolism in chronic kidney disease. **Nat Rev Nephrol** 2017;13:27-38.
 10. Multiphasic effects of blood pressure on survival in hemodialysis patients. Hannedouche T, Roth H, Krummel T, London GM, Jean G, Bouchet JL, Drüeke TB, **Fouque D**. **Kidney Int**. 2016; 90:674-84
 11. Clinical management of the uraemic syndrome in chronic kidney disease. Vanholder R, **Fouque D**, Glorieux G, et al. **Lancet Diabetes Endocrinol**. 2016;4:360-73
 12. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Merle E, Roth H, London GM, Jean G, Hannedouche T, Bouchet JL, Drüeke T, **Fouque D**, Daugas E. **Kidney Int** 2016;89:666-74
 13. The double challenge of resistant hypertension and chronic kidney disease. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, **Fouque D**. **Lancet**. 2015 ; 386:1588-9
 14. Koppe L, Mafra D, **Fouque D**. Probiotics and kidney disease. **Kidney Int**. 2015;88:958-66.
 15. Ortiz A, Covic A, Fliser D, **Fouque D**, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. **Lancet**. 2014;383:1831-43
 16. **Fouque D**, Horne R, Cozzolino M, Kalantar-Zadeh K. Balancing nutrition and serum phosphorus in maintenance dialysis. **Am J Kidney Dis**. 2014;64:143-50.
 17. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, **Fouque D**, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. **N Engl J Med**. 2013;368:2169-81
 18. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, **Fouque D**. The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD. **Clin J Am Soc Nephrol**. 2013;8:819-23
 19. Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, Massy Z, Glorieux G, Vanholder R, Dugenet Y, Soula HA, **Fouque D**, Soulage CO. P-Cresyl sulfate promotes insulin resistance associated with CKD. **J Am Soc Nephrol**. 2013;24:88-99
 20. Pelletier S, Vilayphiou N, Guebre-Egziabher F, **Fouque D**, Chapurlat R. Bone microarchitecture is more severely affected in patients on hemodialysis than in those receiving peritoneal dialysis. **Kidney Int** 82 :581-8, 2012
 21. **Fouque D** et al. Nutrition and chronic kidney disease. **Kidney Int** 80 ; 348-57, 2011
 22. Souberbielle JC, Roth H, **Fouque D**. Parathyroid hormone measurement in CKD. **Kidney Int** 79 ;93-100, 2010